Sources

10 Total Sources

Eli Lilly Lifts 2026 Sales Outlook to $87 Billion on Strong Weight-Loss Drug Demand

Left80%

Center20%

Bloomberg15h ago

Eli Lilly Boosts 2026 Sales Guidance to $87 Billion on Strong Drug Demand

Investors | Eli Lilly and Company15h ago

Eli Lilly Reports 48% Revenue Growth in Q2 2026, Raises Full-Year Guidance on Mounjaro, Zepbound

Here's How Much Traders See Eli Lilly Stock Moving After Earnings - AOL

Eli Lilly Tops Q2 Estimates, Raises Outlook on Zepbound, Mounjaro Sales Surge

LLY | 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 𝐐𝟐 𝟐𝟎𝟐𝟔 𝐄𝐚𝐫𝐧𝐢𝐧𝐠𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: Revenue: $22.97B (↑48% YoY) | GAAP EPS: $7.94 | Adjusted EPS: $8.38 👉 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ➤ 𝐔.𝐒. 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 increased 33% driven mainly by Zepbound

24/7 Wall St.15h ago

Eli Lilly Price Prediction: This Is Where The Stock Will End This Year - 24/7 Wall St.

finance.biggo.com15h ago

Novo Nordisk Q2 Operating Profit Beats Estimates Yet Plunges Over 6%; Investors Shrug Off Upgraded Full-Year Outlook — BigGo Finance

Facebook15h ago

BREAKING: Novo Nordisk, maker of Ozempic and Wegovy, raised its full-year forecast after strong second-quarter profit driven by sales of a new Wegovy tablet, which launched in the US in January and

Stocktwits15h ago

PSKY Beats Q2 Estimates, Raises 2026 Outlook As CEO Stands Firm On $110B WBD Deal — But Stock Slips After-Hours

International Business Times1d ago

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb | IBTimes